Arcutis logo.png
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
February 29, 2024 17:00 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis logo.png
Arcutis Announces Pricing of $150 Million Public Offering
February 28, 2024 23:30 ET | Arcutis Biotherapeutics, Inc.
Arcutis today announced the pricing of its underwritten public offering of common stock.
Arcutis logo.png
Arcutis Announces Proposed Public Offering
February 28, 2024 16:10 ET | Arcutis Biotherapeutics, Inc.
Arcutis today announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock
Arcutis logo.png
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024 05:50 ET | Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter and year ended December 31, 2023, and provided a business update.
Arcutis logo.png
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
December 15, 2023 17:11 ET | Arcutis Biotherapeutics, Inc.
ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration...
Arcutis logo.png
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
November 29, 2023 08:00 ET | Arcutis Biotherapeutics, Inc.
FDA has set a PDUFA target action date of July 07, 2024Atopic dermatitis affects approximately 16.5 million adults and 9.6 million children in the United StatessNDA supported by positive efficacy and...
Arcutis logo.png
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
November 03, 2023 07:30 ET | Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended September 30, 2023, and provided a business update.
Arcutis logo.png
Arcutis to Present at Upcoming Investor Conference
September 05, 2023 16:00 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in...
Arcutis logo.png
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
August 10, 2023 08:16 ET | Arcutis Biotherapeutics, Inc.
Arcutis to receive $30 million upfront payment and is eligible to receive potential development and commercial milestone payments, as well as double digit tiered royalties WESTLAKE VILLAGE,...
Arcutis logo.png
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023 16:02 ET | Arcutis Biotherapeutics, Inc.
Achieved total revenues of $5.2 million in the second quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $4.8 million, a 72% increase compared to the first quarter of...